Have a feature idea you'd love to see implemented?
Let us know!
CGEM Cullinan Oncology Inc
Price (delayed)
$10.01
Market cap
$582.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.84
Enterprise value
$483.22M
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build
Highlights
The debt has declined by 39% year-on-year and by 11% since the previous quarter
The EPS is up by 24% year-on-year and by 7% since the previous quarter
Cullinan Oncology's equity has increased by 34% YoY but it has decreased by 4.3% from the previous quarter
CGEM's quick ratio is up by 20% YoY but it is down by 15% from the previous quarter
Key stats
What are the main financial stats of CGEM
Market
Valuations
Earnings
Shares outstanding
58.23M
Market cap
$582.86M
Enterprise value
$483.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$143.54M
EBIT
-$157.66M
EBITDA
-$157.36M
Free cash flow
-$126.81M
Per share
Balance sheet
Liquidity
EPS
-$2.84
EPS diluted
-$2.84
Free cash flow per share
-$2.17
Book value per share
$10.83
Revenue per share
$0
TBVPS
$11.2
Total assets
$653.25M
Total liabilities
$25.39M
Debt
$2.45M
Equity
$627.86M
Working capital
$567.84M
Debt to equity
0
Current ratio
24.46
Quick ratio
23.88
Net debt/EBITDA
0.63
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-25.3%
Return on equity
-26.5%
Return on invested capital
-35.2%
Return on capital employed
-25.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGEM stock price
How has the Cullinan Oncology stock price performed over time
Intraday
-9.33%
1 week
-13.41%
1 month
-14.81%
1 year
-5.48%
YTD
-17.82%
QTD
-17.82%
Financial performance
How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$187.36M
Net income
-$143.54M
Gross margin
N/A
Net margin
N/A
CGEM's net income is up by 8% YoY
The operating income has contracted by 5% YoY
Growth
What is Cullinan Oncology's growth rate over time
Valuation
What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 24% year-on-year and by 7% since the previous quarter
Cullinan Oncology's equity has increased by 34% YoY but it has decreased by 4.3% from the previous quarter
The price to book (P/B) is 34% lower than the last 4 quarters average of 1.4
Efficiency
How efficient is Cullinan Oncology business performance
Cullinan Oncology's return on equity has increased by 16% YoY and by 7% QoQ
The company's return on assets rose by 15% YoY and by 6% QoQ
CGEM's return on invested capital is up by 15% year-on-year and by 6% since the previous quarter
Dividends
What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGEM.
Financial health
How did Cullinan Oncology financials performed over time
CGEM's total assets is up by 32% year-on-year but it is down by 4.1% since the previous quarter
The current ratio rose by 20% year-on-year but it has declined by 15% since the previous quarter
The debt is 100% smaller than the equity
CGEM's debt to equity has dropped by 100% year-on-year
The debt has declined by 39% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.